Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Trevi Therapeutics reported Q1 2026 financial results and announced the completion of a follow-on common stock offering that generated net proceeds of approximately $162 million. Management stated that the capital raise extends the expected cash runway into 2030, funding the upcoming Phase 3 trial of Haduvio in IPF-related chronic cough and Phase 2b trials in other indications.
Key figures
- Guidance
- Expected cash runway into 2030 through potential FDA approval of Haduvio
- Net loss
- 13200000
- Ga expense
- 5000000
- Rd expense
- 9900000
- Cash runway
- into 2030
- Cash balance
- 171800000
- Net proceeds offering
- 162000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.